Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 May 2024 | Story Jacky Tshokwe | Photo supplied
Reading Culture
The University of the Free State Faculty of Humanities and the Library Information Services proudly established a brand-new school library at Kagisano Combined School on 14 May 2024.

In a bid to cultivate a culture of reading within the community and bolster the University of the Free State's (UFS) Vision 130, the Faculty of The Humanities has embarked on a transformative journey of collaboration with the Library Information Services (LIS). This partnership symbolises a commitment to not only academic excellence, but also social responsibility, aiming to make a tangible difference in the lives of those within our community.

On 14 May, the Dean’s office – in synergy with LIS and the Department of Plant Sciences – undertook a meaningful venture at Kagisano Combined School in Ikgomotseng to establish a school library, making it an engaging and welcoming space for learners.

Led by Dr Dimitri Veldkornet and supported by four dedicated PhD candidates, the Department of Plant Sciences has made a remarkable impact by enhancing the library's surroundings with indigenous flowers. Beyond mere beautification, this initiative also served as an educational opportunity, as five learners from the school were trained to care for these plants, fostering a sense of ownership and environmental stewardship.

Colleagues from LIS meticulously and simultaneously organised the library space, ensuring that reading materials were properly catalogued and shelved for easy access. In addition, LIS generously donated furniture, including shelves, tables, and chairs, to create an inviting environment conducive to learning and exploration.

The collaborative effort extended beyond academic circles, as the community of Ikgomotseng and Letsatsi Trust demonstrated remarkable hospitality by combining resources to provide refreshments for UFS colleagues and community members involved in the initiative. This gesture exemplifies the power of collective action and highlights the interconnectedness between the university and its surrounding communities.

By revitalising the school library and fostering a culture of reading, this partnership exemplifies the core values of social responsibility and community engagement espoused by the UFS. Moreover, it underscores the university's commitment to Vision 130, which envisions a future where education transcends the confines of academia to positively impact society at large.

As we continue to forge ahead, let us remember that true progress is measured not only by academic achievements, but also by the meaningful contributions we make to the communities we serve. Together, through collaboration and compassion, we can create a brighter, more inclusive future for all. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept